methyl-(5-methyl-pyrimidin-2-yl)-amine | 859957-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methyl-(5-methyl-pyrimidin-2-yl)-amine
• 英文别名: Methyl-(5-methyl-pyrimidin-2-yl)-amin；N,5-Dimethylpyrimidin-2-amine
• CAS: 859957-10-1
• 化学式: C₆H₉N₃
• 分子量: 123.158
• InChiKey: HDCAHRAHYJJDSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为产物：
  描述：

  (4-chloro-5-methyl-pyrimidin-2-yl)-methyl-amine 在 水 、 锌 作用下， 生成 methyl-(5-methyl-pyrimidin-2-yl)-amine
  参考文献：
  名称：

  Johnson; Mackenzie, American Chemical Journal, 1909, vol. 42, p. 368

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• DNA-PK INHIBITORS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20130281431A1

  公开（公告）日：2013-10-24

  The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为DNA-PK抑制剂的化合物。该发明还提供了包含所述化合物的药物可接受的组合物，以及使用所述组合物治疗各种疾病、状况或失调的方法。
• NEW COMPOUNDS
  申请人：HAUEL Norbert

  公开号：US20100240669A1

  公开（公告）日：2010-09-23

  The present invention relates to the compounds of general formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

  本发明涉及一般式I的化合物，其中n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和X的定义如下所述，其对映体、非对映体、混合物及其盐，特别是其与有机或无机酸或碱形成的生理上可接受的盐，具有有价值的性质，其制备方法，含有药理学有效化合物的药物，其制备方法和用途。
• Novel Heterocyclic Compounds and Uses Thereof
  申请人：Huang Zilin

  公开号：US20130210818A1

  公开（公告）日：2013-08-15

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代杂环化合物，含有它们的组合物，以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。
• [EN] N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-PYRROLIDINYLE, N'-PYRAZOLYL-URÉE, THIO-URÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078323A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式(I)的化合物或立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、环B和环C如本文所述定义，且环B和NH-C(=X)-NH基团处于反式构型，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些感染性疾病、舍格伦综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。